Lymphomas are malignant tumors originating from the lymphatic system and are divided into two major groups: Hodgkin’s disease and non-Hodgkin’s lymphoma. Currently, there is an average of 1 new patient every 9 minutes worldwide . The incidence rate of lymphoma in China is 0.02 per 1,000. With about 45,000 new patients and nearly 20,000 deaths per year, the threat of lymphoma is rapidly emerging. In Asia, the incidence of non-Hodgkin’s lymphoma is much higher than that of Hodgkin’s disease, about 9:1 , and because of the higher malignancy and poorer prognosis, lymphoma is generally spoken of as non-Hodgkin’s lymphoma. In China, men occupy the 9th place and women the 10th place in the incidence ranking of malignant tumors. Non-Hodgkin’s lymphoma can occur at all ages, and the high incidence age is 45-60 years old. According to the World Health Organization (WHO) pathological classification principles, non-Hodgkin’s lymphoma is subdivided into about 30 subtypes, some with slow progression, others with aggressive disease, and different subtypes are treated differently. Based on the growth rate of the tumor, non-Hodgkin’s lymphoma can be further divided into 3 types, namely inert lymphoma with slow growth, aggressive lymphoma with faster growth and highly aggressive lymphoma with very rapid growth. Since the clinical manifestations, treatment principles and prognosis of different pathological subtypes of lymphoma are different, early and clear pathological diagnosis and pathological subtypes, accurate clinical staging and appropriate treatment plan are the prerequisites to obtain the best treatment effect.